Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Optimism for Lilly’s Trulicity CVOT but hesitance on prior GLP-1 CVOTs benefits

Eli Lilly’s approved type 2 diabetes (T2D) medication Trulicity (dulaglutide) is in a study to assess its impact on cardiovascular risk and triggered mostly cautious optimism for success. Yet, interviewed T2D experts also noted uncertainty still prevails given similar drugs have shown varying results in their respective cardiovascular trials.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top